Table 1 Baseline characteristics and clinical summary of patients with DMD.

Subject IDDMD exon
deletion
Age (years)Weight (kg)BSA (m2)Cumulative
drug dose
during
treatment (mg)
Age at loss of
ambulation
(years)
Corticosteroid
(prednisolone)
regimen
Other drug
treatments at
study entry
Cohort 1 (1.25 mg/kg)
NS-0648–521237.81.24755010NoNo
NS-0545–521636.31.2745201014 mg dailyTeprenone
cimetidine
NS-0248–521448.11,3947208NoNo
Cohort 2 (5 mg/kg)
NS-0445–52823.80.9021,420Ambulant15 mg intermittentFamotidine
NS-0148–521048.81.3492,940Nonambulant*20 mg intermittentNo
NS-0345–521144.31.1502,630910 mg dailyNo
Cohort 3 (20 mg/kg)
NS-0748–521483.41.78919,790128 mg intermittentNo
NS-0945–521326.90.9829,10010NoNo
NS-0849–52839.81.2116,490AmbulantNoNo
NS-1045–52623.40.8485,750Ambulant15 mg dailyCalcium-l-
aspartate

*Nonambulant, but age at loss of ambulation unknown. BSA, body surface area.